The Russian government plans to stimulate the production of active pharmaceutical ingredients (APIs) for the domestic sector, as part of a recent order by the country’s President, Vladimir Putin.
In fact, the plans for localization of ingredients production in Russia were first announced about 10 years ago, although, so far a little progress in this field has been achieved.
At present about 80% of domestic drugs are produced on the basis of raw materials that are supplied to Russia from China and India, while in recent years the volume of such supplies has significantly increased, and the growth is currently ongoing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze